Poster Presentation The 45th Lorne Conference on Protein Structure and Function 2020

Recombinant expression of Insulin-like growth factor-ii analogues for investigation of receptor binding mechanisms (#327)

Andrew AB Blyth 1 , Carlie CD Delaine 1 , Allanah AM Merriman 1 , Briony BF Forbes 1
  1. Medical Biochemistry, Flinders University, Adelaide, SA, Australia

The insulin like growth factor (IGF) system is essential for the regulation of metabolic and mitogenic responses in mammalian cells. This system is regulated by three ligands, IGF-I, IGF-II and insulin, each sharing high degree of sequence and structural homology. The IGF system has been heavily implicated in promoting cancer progression, with several studies linking the upregulation of IGF-II, the insulin receptor isoform-A and IGF-1R with cancer growth and survival.

Currently, there is no structure of the entire IR-A or IGF-1R in complex with IGF-II. Mutagenesis of IGF-II defined two surfaces important for receptor binding (site 1 and 2). However, recent cryo electron microscopy (cryo-EM) structures of insulin and IGF-I complexed to their cognate receptors highlight a discrepancy, where all but one of the site 2 residues defined by mutagenesis are not making contact with the receptor.

Here we aim to use Fluorescence Resonance Energy Transfer (FRET) as a molecular ruler to measure the distance between the receptor and ligand site 2 residues.

We will report the recombinant expression, purification and refold of several IGF-II analogues for FRET analysis. The significance of site 2 to our study is that our preliminary structure/function data suggests this interaction site is involved in the growth promoting functions. To effectively inhibit cancer growth induced by IGF-II binding we need to further map the interactions using a different approach to precisely define the site 2 interaction. Understanding of the molecular mechanisms of activating growth and division will ultimately lead to the development of IGF-II analogues with antagonistic properties for the treatment of cancer.